|
Lenperone
Lenperone (Elanone-V) is a typical antipsychotic of the butyrophenone chemical class. It was first reported as an anti-emetic in 1974, and its use in treatment of acute schizophrenia was reported in 1975. Related early antipsychotic agents include declenperone and milenperone. Lenperone was never approved by the FDA for use in humans in the United States, but prior to 1989 it was approved for use in veterinary medicine for sedation. Synthesis The alkylation between 2-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane 308-94-9(1) and 4-(4-fluorobenzoyl)piperidine 6346-57-7(2) gives 2-(p-fluorophenyl)-2--1,3-dioxolaneCID:20318874(3). Deprotection of the ketal function completes the synthesis of lenperone (4). See also * Glemanserin * Pruvanserin * Roluperidone * Volinanserin Chemically related drugs containing the same 4-(''p''-fluorobenzoyl)piperidine group: * Altanserin * Ketanserin * Setoperone * Lidanserin Lidanserin (International Nonproprietary Name, INN; ZK-33,8 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Lenperone Synthesis
Lenperone (Elanone-V) is a typical antipsychotic of the butyrophenone chemical class. It was first reported as an anti-emetic in 1974, and its use in treatment of acute schizophrenia was reported in 1975. Related early antipsychotic agents include declenperone and milenperone. Lenperone was never approved by the FDA for use in humans in the United States, but prior to 1989 it was approved for use in veterinary medicine for sedation. Synthesis The alkylation between 2-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane 308-94-9(1) and 4-(4-fluorobenzoyl)piperidine 6346-57-7(2) gives 2-(p-fluorophenyl)-2--1,3-dioxolaneCID:20318874(3). Deprotection of the ketal function completes the synthesis of lenperone (4). See also * Glemanserin * Pruvanserin * Roluperidone * Volinanserin Chemically related drugs containing the same 4-(''p''-fluorobenzoyl)piperidine group: * Altanserin * Ketanserin * Setoperone * Lidanserin Lidanserin (International Nonproprietary Name, INN; Z ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Roluperidone
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist under development by Minerva Neurosciences for the treatment of schizophrenia. One of its metabolites also has some affinity for the H1 receptor. Pre-clinical findings provide evidence of the effect of roluperidone on Brain-Derived Neurotrophic Factor (“BDNF”), which has been associated with neurogenesis, neuroplasticity, neuroprotection, synapse regulation, learning and memory. As of May 2018, the drug was in phase III clinical trials. In May 2020, the shares of Minerva Neurosciences plummeted 67% after the trial "failed to meet its primary endpoint of reduction in negative symptoms, and key secondary endpoints of improvement in personal and social performance measurements." However, in August of 2022 Minerva submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for the approval of roluperidone for the treatment of schizophrenia. The ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Volinanserin
Volinanserin ( INN) (developmental code name MDL-100,907) is a highly selective 5-HT2A receptor antagonist that is frequently used in scientific research to investigate the function of the 5-HT2A receptor. It was also tested in clinical trials as a potential antipsychotic, antidepressant, and treatment for insomnia but was never marketed. See also * Glemanserin * Pruvanserin * Roluperidone * Lenperone * Lidanserin * Ketanserin * Ritanserin * Eplivanserin * Pimavanserin Pimavanserin (ACP-103; BVF-036), sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being studied for the treatment of Alzheimer’s disease psychos ... References 5-HT2A antagonists Fluoroarenes Piperidines Secondary alcohols Phenol ethers Abandoned drugs {{nervous-system-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Lidanserin
Lidanserin (International Nonproprietary Name, INN; ZK-33,839) is a drug which acts as a combined 5-HT2A receptor, 5-HT2A and α1-adrenergic receptor, α1-adrenergic receptor receptor antagonist, antagonist. It was developed as an antihypertensive agent but was never marketed. See also * Glemanserin * Pruvanserin * Roluperidone * Volinanserin * Lenperone * Iloperidone * Ketanserin References 5-HT2A antagonists Abandoned drugs Alpha-1 blockers Antihypertensive agents Ketones Fluoroarenes Piperidines Pyrrolidones {{nervous-system-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Glemanserin
Glemanserin (International Nonproprietary Name, INN) (developmental code name MDL-11,939) is a drug which acts as a potency (pharmacology), potent and binding selectivity, selective 5-HT2A receptor, 5-HT2A receptor receptor antagonist, antagonist. The first truly selective 5-HT2A ligand to be discovered, glemanserin resulted in the development of the widely used and even more potent and selective 5-HT2A receptor antagonist volinanserin (MDL-100,907), which is a fluorinated structural analog, analogue. Though it was largely superseded in scientific research by volinanserin, glemanserin was investigated clinical trial, clinically for the treatment of generalized anxiety disorder. However, it was ultimately found to be ineffective and was not marketed. See also * Volinanserin * Pruvanserin * Roluperidone * Lenperone * Lidanserin References 5-HT2A antagonists Secondary alcohols Phenol ethers Piperidines {{nervous-system-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Pruvanserin
Pruvanserin (EMD-281,014, LY-2,422,347) is a selective 5-HT2A receptor antagonist which was under development by Eli Lilly and Company for the treatment of insomnia. It was in phase II clinical trials in 2008 but appears to have been discontinued as it is no longer in the company's development pipeline. In addition to its sleep-improving properties, pruvanserin has also been shown to have antidepressant, anxiolytic, and working memory-enhancing effects in animal studies. See also * Eplivanserin * Pimavanserin * Glemanserin * Roluperidone * Volinanserin * Ziprasidone * Lenperone Lenperone (Elanone-V) is a typical antipsychotic of the butyrophenone chemical class. It was first reported as an anti-emetic in 1974, and its use in treatment of acute schizophrenia was reported in 1975. Related early antipsychotic agents includ ... * Lidanserin References {{Serotonergics 5-HT2A antagonists Eli Lilly and Company brands Indoles Aromatic nitriles N-benzoylpiperazines ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Piperidines
Piperidine is an organic compound with the molecular formula (CH2)5NH. This heterocyclic amine consists of a six-membered ring containing five methylene bridges (–CH2–) and one amine bridge (–NH–). It is a colorless liquid with an odor described as objectionable, and typical of amines. The name comes from the genus name ''Piper'', which is the Latin word for pepper. Although piperidine is a common organic compound, it is best known as a representative structure element within many pharmaceuticals and alkaloids, such as natural-occurring solenopsins. Production Piperidine was first reported in 1850 by the Scottish chemist Thomas Anderson and again, independently, in 1852 by the French chemist Auguste Cahours, who named it. Both of them obtained piperidine by reacting piperine with nitric acid. Industrially, piperidine is produced by the hydrogenation of pyridine, usually over a molybdenum disulfide catalyst: : C5H5N + 3 H2 → C5H10NH Pyridine can also be reduce ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Butyrophenone Antipsychotics
Butyrophenone is an organic compound with the formula C6H5C(O)C3H7. It is a colorless liquid. The butyrophenone structure—a ketone flanked by a phenyl ring and a butyl chain—forms the basis for many other chemicals containing various substituents. Some of these butyrophenones are used to treat various psychiatric disorders such as schizophrenia, as well as acting as antiemetics. Examples of butyrophenone-derived pharmaceuticals include: * Haloperidol, the most widely used classical antipsychotic drug in this class * Benperidol, the most potent commonly used antipsychotic (200 times more potent than chlorpromazine) * Droperidol, Antiemetic for postoperative nausea and vomiting Postoperative nausea and vomiting (PONV) is the phenomenon of nausea, vomiting, or retching experienced by a patient in the postanesthesia care unit (PACU) or within 24 hours following a surgical procedure. PONV affects about 10% of the population ... References Aromatic ketones Phenyl compou ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Setoperone
Setoperone is a compound that is a ligand to the 5-HT2A receptor. It can be radiolabeled with the radioisotope fluorine-18 and used as a radioligand with positron emission tomography (PET). Several research studies have used the radiolabeled setoperone in neuroimaging for the studying neuropsychiatric disorders, such as depression or schizophrenia. Synthesis The starting material is called 6-(2-hydroxyethyl)-7-methyl-2,3-dihydro- ,3hiazolo ,2-ayrimidin-5-oneCID:15586462(1). Halogenation of this with hydrobromic acid in acetic acid giveCID:15586463(2). Sn2 alkylation with 4-(4-fluorobenzoyl)piperidine 6346-57-7(3) under Finkelstein reaction conditions affords setoperone (4). See also * Altanserin * Ketanserin * Pirenperone Pirenperone (, , ; developmental code names R-47456, R-50656) is a serotonin receptor antagonist described as an antipsychotic and tranquilizer which was never marketed. It is a relatively selective antagonist of the serotonin 5-HT2 recepto ... * R ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ketanserin
Ketanserin (INN, USAN, BAN) (brand name Sufrexal; former developmental code name R41468) is a drug used clinically as an antihypertensive agent and in scientific research to study the serotonin system; specifically, the 5-HT2 receptor family. It was discovered at Janssen Pharmaceutica in 1980. It is not available in the United States. Uses Medical uses Ketanserin is classified as an antihypertensive by the World Health Organization and the National Institute of Health. It has been used to reverse pulmonary hypertension caused by protamine (which in turn was administered to reverse the effects of heparin overdose). The reduction in hypertension is not associated with reflex tachycardia. It has been used in cardiac surgery. A 2000 Cochrane Review found that, compared to placebo, ketanserin did not provide significant relief for people suffering from Raynaud's phenomenon attacks in the setting of progressive systemic sclerosis (an autoimmune disorder). While the frequency of t ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Typical Antipsychotic
Typical antipsychotics (also known as major tranquilizers, and first generation antipsychotics) are a class of antipsychotic drugs first developed in the 1950s and used to treat psychosis (in particular, schizophrenia). Typical antipsychotics may also be used for the treatment of acute mania, agitation, and other conditions. The first typical antipsychotics to come into medical use were the phenothiazines, namely chlorpromazine which was discovered serendipitously. Another prominent grouping of antipsychotics are the butyrophenones, an example of which is haloperidol. The newer, second-generation antipsychotics, also known as atypical antipsychotics, have largely supplanted the use of typical antipsychotics as first-line agents due to the higher risk of movement disorders in the latter. Both generations of medication tend to block receptors in the brain's dopamine pathways, but atypicals at the time of marketing were claimed to differ from typical antipsychotics in that they are ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
